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Abstract
We have previously reported that ectopically expressed Factor (F) VIII is stored within platelets and is released upon platelet activation. Studies in various cell lines by others have suggested that having Von Willebrand Factor (VWF) coexpression was necessary for FVIII granular storage and for its secretion. We tested the importance of VWF coexpression for ectopic storage of FVIII in platelets and for its bioavailability. Transgenic mice expressing platelet-specific FVIII were crossed onto a VWF -/-background. Antigenic levels of platelet FVIII in these mice were nearly unchanged whether VWF was present or not. Whole blood clotting times and FeCl 3 carotid artery injury correction demonstrated that platelet FVIII demonstrably improved the bleeding diathesis in FVIII null mice independent of the platelets' VWF status. Immunogold electron microscopy demonstrated that platelet FVIII is stored in platelet -granules independent of the presence of VWF. It appears that FVIII's interaction with VWF and its intracellular transportation, storage and secretion differ greatly depending on the cell type. The molecular basis for these differences now need to be elucidated. We now addressed whether FVIII needs VWF for granular storage during megakaryopoiesis.
Part of our motivation was that we had already observed that FVIII processing in megakaryocytes differed from that in CHO cells in that it was not secreted. In addition, such studies may provide a better understanding of the limitations of utilizing platelets to deliver an ectopic protein to a site of interest.
We, therefore, crossed the transgenic mouse expressing platelet human B-domainless FVIII (hB-FVIII) with the previously described VWF gene-targeted disruption mouse 6 , and examined the resulting mice for FVIII antigen and activity, and for localization within the platelet. These studies showed that FVIII was efficiently stored in platelets independent of whether VWF was coexpressed. Upon platelet activation, the released FVIII was also equally biologically active independent of whether the platelets coexpressed VWF in a whole blood clotting time (WBCT) assay in an in vivo thrombosis model. Immunogold electron microscopy (EM) confirmed that most of the FVIII was found inside -granules, independent of whether VWF was coexpressed.
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Materials
Characterization of the studied mice. The mouse models allowing this study have been previously described. The VWF gene targeted disruption mice involved a loss of exons 4 and 5 of the VWF gene with no VWF protein expression 6 . The FVIII null mice had a targeted disruption of Exon 16 of the FVIII gene 7 . Platelet hB-FVIII transgenic mice were generated as previously Determination of hFVIII antigenic and functional levels. Levels of hB-FVIII antigen in the plasma and platelets of transgenic animals were determined using an anti-human-specific FVIII ELISA kit (Affinity Biological Inc., Hamilton, Canada) in platelet releaste from platelet-rich plasma after activation by phorbol ester and collagen, comparing levels to hB-FVIII recombinant protein (ReFacto Laboratory Standard, Genetics Institute, Cambridge, MA) 2 . FVIII activity level was determined by WBCT 2, 8 . Results of both antigen and activity were determined per mL of blood sample, per platelet count and relative to another alpha-granule-specific protein, determined as previously described by us 9 . FeCl 3 -induced arterial injury was also performed according to published procedures 2, 10 . In some experiments, the animals received an infusion of washed platelets obtained from the inferior venae cavae of a single donor mouse to avoid plasma transfer prior to the application of the FeCl 3 injury as previously described 1,2 .
Immunogold electron microscopy. Washed platelets from individual mice were fixed and transported to Bordeaux at 4°C as in 11 . Preparation of ultrathin cryosections, antibody labeling and EM were performed 11, 12 . Antibodies used were: rabbit polyclonal anti-human VWF (Dako, 
Results and Discussion
Determination of platelet FVIII antigenic and functional levels. The hB-FVIII mice expressed ~9 U of FVIII antigen in their platelets found in 1 mL of whole blood, which we have termed a plasma equivalency of ~9% 2 . To define the importance of VWF for the presence of FVIII in platelets, ELISA studies of plasma and platelet releasate for hB-FVIII was done on hB-FVIII/FVIII null mice that were either VWF +/+ or VWF +/-or VWF -/-( Figure 1A ). The platelet level on a heterozygote background was nearly identical to that of the wildtype animal, but on the VWF -/-background it was 73 ± 7% of the wildtype level (n=12 per arm, p <0.05). Since platelet counts and platelet factor 4 levels were identical among the 3 groups (data not shown), the results were also true when expressed on a per platelet basis. No FVIII activity was detected in any of the concurrently studied plasma samples (data not shown). WBCT studies are a particularly effective means of measuring platelet FVIII availability 2 . Measurements done with similar animals as described above gave no difference whether VWF was present or not (n= 5
per each arm, Figure 1B) There are several explanations for the ~25% decrease in platelet FVIII antigen on the VWF background (Fig. 1A) . These include the possibility that VWF affects platelet FVIII half-life by altering its storage site or its stability in that storage space or that without VWF, some FVIII is secreted. Since this released FVIII would be in small amounts and since there would be no VWF to stabilize the circulating FVIII in these mice, the fact that there was no detectable plasma FVIII in the hB-FVIII/FVIII null /VWF -/-mice does not eliminate the possibility that a portion of the platelet FVIII was secreted. To better understand the fate of the platelet FVIII, immunogold electron microscopy was carried out. In the hB-FVIII/FVIII null /VWF +/+ mice, the FVIII was mostly localized to -granules ( Fig. 2A) , often occurring in the same granules as the VWF, although labeling were not always co-adjacent with the detected VWF. The platelet FVIII was found in similar granules and frequency in the hB-FVIII/FVIII null /VWF -/-mice (Fig. 2B ). As expected VWF was absent, but these granules did contain fibrinogen, another -granular protein 13 ( Fig. 2C) . No labeling was seen with an irrelevant mouse IgG (data not shown).
Thus, these studies support -granular localization of ectopically expressed FVIII in platelets in a VWF-independent fashion. This provides further support for differences in intracellular processing of FVIII between cell types. In megakaryocytes, ectopically expressed FVIII is not secreted, but stored in -granules, independent of co-expressed VWF. In contrast in fibroblast CHO cells, FVIII intracellular processing and secretion is markedly dependent on coexpressed VWF 3 , and in neural AtT-20 cells, FVIII intragranular storage is dependent on coexpressed VWF 5 . DDAVP infusions in liver transplantation subjects 14 and after gene therapy in dog models 15 suggest that liver cells only secrete FVIII, while endothelial cells may store FVIII along with VWF in Weibel-Palaade bodies. The molecular basis for these differences in intracellular processing needs to be determined.
Another implication of these observations is that it is likely that variants of FVIII with decreased binding to VWF may still be stored in platelet -granules. For example, platelet delivery of the 
